MedTrace Logo

Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

NCT00502528 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2013-04-30

No results posted yet for this study

Summary

Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.

Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.

Conditions

  • ST-Elevation Myocardial Infarction

Interventions

DRUG

Placebo

Peri-interventional

DRUG

BQ-123

Peri-interventional

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Irene M Lang, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-08-31
Completion
2012-08-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502528 on ClinicalTrials.gov